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Recent advances in genetic analysis are bringing huge benefits to patients 
with rare genetic disorders, including those with inherited disorders of platelet 
number and function. Modern clinical hematological practice now has a range 
of genetic techniques available to enable the precision diagnosis of inherited 
platelet disorders. There are some features of this disparate group of inherited 
disorders that present specific challenges to establishing an accurate genetic 
diagnosis. This review aims to introduce the techniques that are relevant for 
the genetic diagnosis of inherited platelet disorders and will discuss the key 



















Recent advances in the molecular diagnostic laboratory are bringing huge 
benefits to patients with rare genetic disorders, including inherited platelet 
disorders (IPD; disorders of platelet number and/or function). Hematology 
clinicians now have a range of genetic techniques available for diagnosis of 
IPD in individuals and pedigrees. However, there are some features of IPD 
that present challenges to genetic diagnosis. This review aims to introduce to 
the techniques that are relevant for genetic diagnosis of IPD and highlights 
some important considerations necessary for clinical application. 
 
The relevance of achieving a genetic diagnosis in IPD 
IPD are large group of genetically heterogeneous disorders, which may have 
similar clinical and laboratory characteristics to common acquired platelet 
disorders. Moreover, the different IPD are often difficult to distinguish from 
each other, yet may vary in heritability and prognosis, and may require 
different interventions.  
 
One immediate benefit from diagnosis at genetic level is that it enables more 
precise classification of IPD, enabling better prediction of clinical risk of 
bleeding and syndromic comorbidities. For example, in pedigrees with 
autosomal dominant thrombocytopenia, genetic diagnosis of CYCS-related 
thrombocytopenia (CYCS) usually indicates favourable outcomes because 
there are no known associated features other than thrombocytopenia and low 
risk of bleeding1. In contrast, diagnosis of familial platelet disorder with a 
predisposition to acute myeloid leukaemia (RUNX1), which may be clinically 
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indistinguishable from CYCS-related thrombocytopenia at presentation, has 
different implications because bleeding is more likely as platelets are 
dysfunctional as well as reduced in number. Moreover, there is an 
approximately 40% risk of developing myeloid malignancy2. Detecting some 
types of IPD may inform selection of specific treatments, such as the use of 
TPO receptor agonists to temporarily correct thrombocytopenia in MYH9-
related disorder (MYH9-RD)3,4 and DIAPH1-related disorder5. Moreover, 
correctly distinguishing heritable thrombocytopenia from immune 
thrombocytopenia reduces the likelihood of ineffective and potentially 
dangerous therapies such as corticosteroids, intravenous immunoglobulins 
and splenectomy. In addition to clinical benefits to index cases with IPD, 
genetic diagnosis also benefits pedigree members by allowing robust 
detection of disease when phenotype testing is difficult and by enabling 
prediction of risk of disease in subsequent generations. 
 
Phenotypic challenges and genetic heterogeneity in IPD 
The widely-adopted phenotype-driven diagnostic pathway for IPD typically 
comprises clinical evaluation, then initial laboratory tests such as the full blood 
count, examination of the peripheral blood smear or bone marrow, platelet 
function testing and/or measurement of platelet surface protein expression by 
flow cytometry. This may be followed by more specialised investigations, such 
as examination of platelet ultrastructure by electron microscopy or specific 
functional tests such as measurement of dense or alpha granule release6, 




For a minority of IPD in which there are distinctive clinical or laboratory 
characteristics, systematic evaluation of phenotype may sometimes be 
sufficient for diagnosis of a specific disorder to the level of abnormal protein or 
protein complex. These IPD generally are associated with severe, highly 
penetrant phenotypes such as Glanzmann thrombasthenia (ITGA2B, ITGB3), 
or unmistakable syndromic presentations such as Chediak-Higashi syndrome 
(LYST) in which there are characteristic laboratory features. However, for 
most patients with IPD that lack a distinctive presentation, this approach is 
insufficient for precision diagnosis and at best, enables detection of defects at 
cellular or biological pathway level only7,8.  
 
Efforts to standardise precision diagnosis in IPD are further hampered by the 
marked genetic heterogeneity of the known IPD. Considering the 56 currently 
known genes (as at June 2018) associated with IPD (Table 1), variants in a 
number of different genes can be associated with similar phenotypes 
observed in the clinic or phenotyping laboratory. For example, the association 
of autosomal dominant macrothrombocytopenia and sensorineural deafness 
previously thought to be pathognomonic of MYH9-RD is now known to also be 
a feature of DIAPH1-related disorder (DIAPH1)9-11. Amongst the platelet 
function disorders, severe bleeding and reduced platelet responses to multiple 
activating agonists are typically associated with Glanzmann thrombasthenia in 
which there is defective platelet surface expression of the IIb3 integrin. 
However, these may also be features of several more recently discovered 
disorders such as CalDAG GEFI deficiency (RASGRP2) and leukocyte 
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adhesion deficiency III (FERMT3) in which there are defects in proteins that 
are functionally associated with the IIb3 integrin12,13. 
 
Conversely, different variants in some individual genes may be associated 
with markedly different phenotypes of IPD. For example, in MYH9-RD, 
variants affecting the head domain of the non-muscle myosin heavy chain IIA 
(NMMHC-IIA) protein were found to be associated with a higher incidence of 
nephropathy and deafness than variants affecting the tail domain14. Further 
analysis of a larger collection of patients with MYH9-RD has revealed that 
specific variants within the same domain of NMMHC-IIA result in altered 
expressivity of the disorder, even when different variants affect the same 
amino acid residue15.  
 
In order to overcome these challenges, genetic testing strategies have 
progressed from using characteristic IPD phenotype to select individual 
candidate genes for confirmatory testing. Instead, new technologies now 
increase the scope of genetic diagnosis by enabling simultaneous 
examination of panels of known IPD genes or even identification of new IPD 
genes using more expansive sequencing approaches techniques coupled with 
bioinformatic and statistical genetic analyses.  
 






In this approach, individual genomic DNA sections of typically 100-1000 base 
pairs are amplified by the polymerase chain reaction (PCR) using locus-
specific primers designed to flank regions of the gene of interest16. The  
PCR amplicons are then purified before chain termination sequencing to 
generate individual sequence traces corresponding to each PCR amplicon16-
18. Using Sanger methodology, candidate causal variants are identified by 
comparing single sequence reads to reference sequence.  
 
Although Sanger sequencing has historically been the reference standard 
method for detection of pathogenic variants in IPD, the technology is 
necessarily time consuming and has high cost. This restricts the application of 
Sanger sequencing to small genomic regions containing individual genes of 
interest. Therefore, Sanger sequencing is best suited to situations where 
single or small numbers of candidate genes can be selected because of 
characteristic clinical or laboratory phenotypes that are highly suggestive of a 
specific disorder. In these situations, achieving genetic diagnosis by Sanger 
sequencing can be seen as confirming the clinicopathological diagnosis 
already reached on the basis of phenotype testing alone.  
 
High throughput sequencing 
High throughput sequencing (HTS, also referred to as next generation 
sequencing or massively parallel sequencing) is the overarching term used to 
describe modern sequencing technologies using platforms such as Illumina19, 
Roche 45420 and Ion Torrent21. These technologies all utilise fragmented 
genomic DNA samples that undergo an amplification step using PCR-based 
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technologies. However, the main differences between the technologies are in 
the way that nucleotide sequence is detected and outputted. For clinical 
applications, it is convenient to divide the HTS approaches into gene panels 
and whole exome sequencing (WES) which target particular areas of the 
genome, and whole genome sequencing (WGS) which is not restricted to 
specific regions.  
 
Gene panels 
Gene panel sequencing involves the targeted sequencing a group of typically 
10-100 genes that are associated with a particular disease or phenotype. In 
most examples, bait panels of oligonucleotide primers are designed to target 
the exons, flanking intronic sequence that includes the splice regions and 
selected regulatory regions of the relevant genes. This approach is usually 
applied for diagnosis of monogenic disorders for which there are several 
candidate genes that cannot easily be resolved using clinical and laboratory 
phenotype (Table 1). For example, autosomal dominant 
macrothrombocytopenia without additional syndromic features may be 
associated with variants in several genes, including ACTN1, FLNA, GP1BB, 
TPM4 and TUBB1. It may be possible to distinguish some of these alternate 
diagnoses using phenotype tests such as flow cytometry or platelet 
ultrastructural analysis4,22,23. However, these tests are not widely available in 
clinical laboratories, are expensive, and are poorly standardised at present. In 
contrast, sequence analysis of a panel of multiple genes associated with 
macrothrombocytopenia is faster and more cost effective than Sanger 




Gene panels usually allow deeper coverage of the regions of interest for a 
given number of reads than can be achieved using WES, thereby increasing 
diagnostic accuracy. Custom bait designs for gene panels can also enable 
higher quality sequencing of otherwise inaccessible genomic regions that are 
difficult to evaluate using non-custom bait libraries such as whole exome 
panels. A significant economic benefit of gene panel sequencing is that it 
facilitates multiplexing, where several samples are sequenced simultaneously. 
However, one key disadvantage is that since the bait panels are custom 
designed to include only the genes of interest, the approach is not resilient to 
discoveries of new genes associated with a given phenotype. Consequently, 
gene panels typically require redesign to include new implicated genes, 
particularly in areas of frequent gene discovery.  
 
The panel approach has been applied for genetic diagnosis of several groups 
of heritable disorders, including monogenic forms of dyslipidaemia24, cardiac 
dysrhythmias25 and anaemia26. For the IPD, the ThromboGenomics gene 
panel has been successfully validated in a range of different IPD and has now 
entered clinical diagnostic practice in the UK for analysis of IPD genes 
alongside other genes implicated in bleeding and thrombotic disorders27. 
Although the sensitivity (>90%) and specificity (>99.5%) of the original 
ThromboGenomics panel was high when considering cases with a suspected 
molecular aetiology, it remains to be seen whether this will be maintained as 
more potentially causal genes are added to the panel, and as access to the 
panel is broadened. The current ThromboGenomics panel (version TG3.0) 
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includes the coding and key regulatory regions of 100 genes associated with 
58 disorders, including disorders of the vessel wall that may cause bleeding 
such as hereditary haemorrhagic telangiectasia and some subtypes of Ehlers 
Danlos syndrome (http://thrombo.cambridgednadiagnosis.org.uk/gene-
disorder-list/). The content of the panel is reviewed at regular intervals and 
variants are reported according to American College of Medical Genetics and 
Genomics (ACMG) guidelines28 by a multidisciplinary team that includes a 
laboratory scientist and a clinical haemostasis expert. Candidate causal 
variants are then validated using Sanger sequencing to ensure compliance 
with current UK diagnostic quality guidelines.  
 
Elsewhere in the UK, HTS using gene panels has been applied as a research 
tool in the Genotyping and Phenotyping of Platelets (GAPP) study as a means 
of identifying new candidate genes for IPD29. A similar panel has been 
developed by researchers in the Iberian peninsula30, and includes the exons, 
untranslated regions and flanking sequence of 72 genes linked to known IPDs 
or which are otherwise believed important in platelet biology.  
 
Whole exome sequencing  
For WES, there are several commercially available bait libraries that enable 
capture and amplification of the exons and short intronic flanking sequences 
including splice sites of all coding genes, plus other relevant non-coding 
functional sequence. WES bait libraries typically capture 30-60 Mb of 
sequence corresponding to 1-2% of the genome, although there are minor 
differences in the coverage between the commercial exome capture 
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libraries31. Compared to gene panels, the greatly increased number of genes 
that are covered by WES potentially increases the repertoire of disorders that 
can be detected in each analysis, primarily by enabling gene discovery in 
parallel with diagnosis. However, this also results in a greatly increased 
number of observed bystander variants that must be distinguished from 
potentially causal IPD variants.  For WES bait libraries, this is typically in the 
region of 20,000 single nucleotide variants per individual, but with greater 
numbers observed in non-Caucasian subjects32. Bystander variants may 
include potentially pathogenic variants in targets such as cancer susceptibility 
genes which may be unrelated to IPD, but which may have other health 
impacts. 
 
Several different research groups have utilised WES has a research tool to 
identify pathogenic variants in patients with undiagnosed IPD. This included a 
subgroup of cases recruited to the UK GAPP study29,33,34 and the pilot phase 
of the NIHR BRIDGE (www.nihr.ac.uk/about-us/how-we-are-managed/our-
structure/infrastructure/bioresource.htm) Bleeding and Platelet Disorders 
study35. Examples of new genes identified by WES in IPD pedigrees include 
SLFN14 which results in bleeding resulting from thrombocytopenia and an 
additional platelet secretion defect36. After confirmation that SLFN14 variants 
underlie IPD in other study collections, this initial WES discovery has now 
enabled this gene to be included as a target gene on the ThromboGenomics 
clinical diagnostic panel. A similar diagnostic HTS approach developed in 
Scandinavia utilises WES and analysis of 87 genes implicated in inherited 




Whole genome sequencing 
WGS refers to analysis of the entire genome, including coding regions and 
non-coding regions that include proximal and distal regulatory elements. 
There is emerging evidence for involvement of variants in non-coding regions 
in human disease38 and advances in the annotation of the non-coding regions 
now makes detection of pathogenic variants more achievable39. WGS avoids 
the need for exon capture, which may be inefficient in some regions and result 
in coding sequence variants being missed by WES or gene panel sequencing. 
Although initially prohibitively expensive, the cost of WGS has now fallen to 
less than 1000 USD per genome40, making WGS an increasingly cost-
effective option in the diagnostic as well as research setting. Moreover, WGS 
utilises a single genome capture library that can be used for all disease or 
phenotype groups, thereby enabling better standardisation and quality 
assurance. Similar to WES, a single WGS analysis yields a data set for 
individual patients that can be stored and re-evaluated if there are new 
relevant gene discoveries, without the need for further analysis of samples in 
the laboratory. 
 
WGS has been adopted widely in large-scale gene discovery programmes 
such as the NIHR BioResource - Rare Diseases 
(https://bioresource.nihr.ac.uk/rare-diseases/rare-diseases/) and the UK 
100,000 Genomes Project (www.genomicsengland.co.uk). WGS has already 
enabled the discovery of several important new IPD, including platelet number 
disorders caused by variants in DIAPH1, TPM4, and SRC10,41,42. Other 
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discoveries enabled by WGS include definition of new modes of inheritance of 
an IPD (autosomal dominant thrombocytopenia with GPIBB variants) and 
extensions of genotype-phenotype relationship in other disorders such as 
CalDAG GEFI deficiency (RASGRP2) 43,44. Although the key advantage of 
WGS at this stage is in gene discovery, as the proven mutational spectrum of 
disease-associated variants expands into the non-coding regions of the 
genome, WGS will be the only practical way to detect all potentially relevant 
variants. 
 
The capacity of WGS to detect non-coding variants enables detection of 
causal variants underlying most forms of Thrombocytopenia absent radius 
syndrome (RBM8A) and Quebec platelet disorder (PLAU)45,46, which are 
associated with variants in regulatory regions outside coding exons. Non-
coding regulatory regions are also good candidate regions for causal variants 
in the approximately 40% of Mendelian IPD which cannot currently be 
assigned to specific genes47. This is particularly relevant for some sub-groups 
of IPD such as non-syndromic disorders of platelet secretion, for which causal 
genetic variants are usually elusive using current analysis approaches7.  
 
Detection of large structural variants and complex rearrangements 
A small subgroup of IPD may be associated with large copy number variants 
(CNVs) or complex structural rearrangements at chromosomal level. 
Examples include Paris-Trousseau thrombocytopathy which may be a feature 
of Jacobsen syndrome (haploinsufficieny of FLI1 because of interstitial 
terminal deletions of 11q)48 or Di George’s syndrome (haploinsufficincy of 
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ITGBA because of deletions that include 22q11.2)49. These diagnoses are 
often suspected because of characteristic syndromic features and are usually 
de novo presentations in families. However, gene panels or WES may be 
unsuitable because in these technologies sequence reads are not contiguous 
over large genomic regions. 
 
Detection is usually achieved using a technique such as array comparative 
genomic hybridisation (aCGH) in which fluorophore labelled fragmented DNA 
samples are hybridised to an immobilised library of overlapping reference 
genomic DNA fragments of 100-200 kilobase pairs. In most clinical diagnostic 
applications of this approach, copy number variants in the range 5-10 
kilobases may be detected by demonstrating failure of hybridisation with 
specific targets50. However, there is also now emerging data suggesting that 
WGS enables detection of large copy number variants by demonstrating 
changes in read coverage in either deleted or duplicated regions compared 
with reference sequence51,52. 
 
ANALYSIS OF HIGH THROUGHPUT SEQUENCE DATA  
Although HTS has revolutionised diagnostic genetic testing and gene 
discovery in many rare disorders, resolution of causal genetic variants from 
irrelevant bystander variants remains a potential barrier to widespread 
implementation. In parallel with the development in HTS technologies, there 
have been other significant advances in analysis of phenotype and genotype 
data that have improved the utility of HTS for genetic diagnosis and for new 




Systematic description of phenotype 
In order to facilitate interrogation of HTS data, there have been several 
initiatives to standardise description of phenotypes. One such approach that 
has been successfully applied to IPD and other rare disorders is the Human 
Phenotype Ontology (HPO), which is a system of descriptive terms for clinical 
and laboratory phenotypes, but also additional characteristics such as pattern 
of inheritance and age of onset53. One important attribute of the HPO system 
is that it includes both general terms or leading classes (e.g. Abnormality of 
blood and blood forming tissues) and specific terms (e.g. Absence of alpha 
granules) structured in a hierarchical way so that complex phenotypes can be 
described in strings of terms to facilitate comparison between individuals 
(Figure 1) 54,55.  
 
Annotation of IPD phenotypes using HPO terms enables streamlining of data 
sharing between research groups, genotype-phenotype databases, biobanks 
and clinical registries. HPO coding is also now used in clinical diagnostic 
services such as the ThromboGenomics panel, where HPO coded 
phenotypes assist standardisation of variant calling in the panel genes27. HPO 
terms have also been adopted by the UK 100,000 Genomes Project, as a way 
of helping automated selection of which panels of genes are prioritised within 
patients’ WGS sequence datasets for reporting. 
 
In gene discovery projects HPO terms from different individuals can be 
compared using statistical genetic approaches to identify groups of cases with 
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similar phenotypes, even though similarity may not be evident considering 
cases in isolation. This is exploited in statistical genetic analysis techniques 
such as similarity regression which assumes that groups of unrelated cases 
with HPO terms that are mathematically similar, but dissimilar to other cases, 
are likely to have the same underlying genetic disorder35 56. HPO terms in 
cases can also be compared mathematically to animal genetic disease 
models described using Mammalian Phenotype Ontology (MPO) terms to 
assist identification of new human disease candidates in orthologous genes. 
Examples of new IPD successfully identified using HPO-based similarity 
regression and MPO ortholog searching include DIAPH1-related disorder10 
and thrombocytopenia with myelofibrosis and bone defects caused by 
variants in SRC42 respectively. 
 
Variant prioritisation 
Irrespective of the choice of sequencing technology, candidate causal genetic 
variants can only be identified after comparison to the reference human 
genome sequence at that locus. For Sanger sequencing of a single candidate 
gene, this is relatively simple using alignment software such as NCBI BLAST 
(Basic Local Alignment Search Tool)57. However, for HTS techniques, the 
complexity of sequence data requires other sequence alignment approaches 
and bioinformatics tools to enable calling of variants27,30,34,35,37. These include 
important considerations about sequence read quality and coverage of target 





In order to help resolve candidate causal variants from bystander variants in 
large HTS datasets, sequence analysis requires several stages of variant 
filtering. This usually includes elimination of observed variants that are 
common or low frequency in population datasets, preferably derived from 
cohorts of the same ethnicity as the patient. The rationale for this approach is 
that the majority of pathogenic variants are rare in human populations 
because of negative selection pressure. Therefore, a very uncommon disease 
such as an IPD is most likely to be caused by a rare variant (allele frequency 
<0.001), particularly for dominant diseases. Commonly used resources to 
determine the population variant frequencies are the 1000 Genomes, UK10K 
and GnomAD (ExAC) datasets which contain a mixture of WES and WGS 
data generated through disease-specific and population genetic studies32,59. 
Care is needed to ensure that the frequency threshold for eliminating variants 
is appropriately set, particularly for recessive disorders in which homozygous 
or compound heterozygous inheritance of low frequency or even some 
common variants may be sufficient for disease. Amongst the IPD, this is 
illustrated by thrombocytopenia absent radius syndrome (RBM8A) in which 
co-inheritance of a low frequency regulatory variant and a rare variant 
underlies most reported cases45. 
 
Further semi-automated assessment of observed variants usually occurs by 
annotating the variants to predict the likely effect on transcript or protein with 
tools such as the Variant Effect Predictor. This utilises aggregated data from 
Ensembl and other sources to classify whether genomic DNA variants are for 
example, missense, synonymous coding or intronic, relative to the canonical 
 
 18 
transcript of the gene60. Annotation enables variants to be prioritised for 
further consideration if they are predicted to have a large effect on protein 
expression because they are frameshift insertions or deletions, stop-gain or 
stop-loss missense variants, or if they disrupt splice donor or acceptor sites. 
Missense coding variants may also be prioritised using tools such as SIFT or 
PolyPhen61,62 or the CADD score63, which predict pathogenicity using 
computational criteria. Since these tools utilise different combinations of 
criteria to predict pathogenicity, it is usual practice to analyse candidate 
variants using multiple tools and progress variants for further analysis only if 
there is consensus between tools37.  
 
Gene and variant level reporting 
Further shortlisting of candidate variants usually then requires consideration 
of several disease-specific criteria to help confirm pathogenicity. The first of 
these is to consider whether the variant occurs in a gene that has been 
previously associated with the disease phenotype of the case and with 
appropriate heritability (gene level reporting). An initiative to standardise of the 
selection of candidate genes for IPD and other haemostatic disorders has 
been initiated by the Genomics in Thrombosis and Haemostasis Scientific and 
Standardization Committee (SSC) of the International Society on Thrombosis 
and Haemostasis (ISTH) 
(https://www.isth.org/members/group.aspx?id=104628) and more generally in 
rare diseases by the and the Clinical Genome Resource (ClinGen)64. For 
example, the ClinGen proposal classifies an association between disease and 
a candidate gene as Definitive if there are numerous independent reports of 
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unrelated pedigrees with variants in the candidate gene in addition to strong 
evidence from experimental studies for causality that are upheld over time 
with no significant contradictory evidence. Clarification of conflicting 
interpretations of disease-gene associations is resolved through expert 
working groups64.  
 
Prioritised variants may then be further assessed by considering whether 
within implicated genes, individual variants are likely to be pathogenic (variant 
level reporting). One way of achieving this is to identify whether individual 
variants, or similar variants at protein level have been associated previously 
with the phenotype observed in the case. Publicly available variant databases 
are a valuable tool for variant level reporting. For IPD, these include several 
curated disease-specific databases such as the Glanzmann thrombasthenia 
and platelet type von Willebrand disease resources that are maintained under 
the auspices of the ISTH (https://www.isth.org/page/RegistriesDatabases). 
IPD data are also commercially available through more general initiatives 
such as Human Genome Mutation Database (HGMD)65. One important 
caution about the use of historical datasets to assist variant reporting is that 
some datasets may be incompletely curated and contain non-pathogenic 
variants that have incorrectly been associated with a disease phenotype. The 
potential clinical consequences of this are highly significant and include 
incorrect assignment of pathogenicity to observed variants in new cases. 
Efforts to standardise and independently curate human disease variant 
databases have recently been progressed by the development of the publicly 
accessible ClinVar variant database, which aggregates submissions from 
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research groups and clinical laboratories curated by panels of independent 
experts66,67.  
 
Standardisation of variant reporting 
Across rare diseases, including IPD, there is an emerging priority to 
standardise variant level reporting to maintain quality in clinical diagnostic 
testing. Guidelines for the classification of variants have recently been 
disseminated by the American College of Medical Genetics and Genomics 
(ACMG) and the Association for Molecular Pathology (AMG)28 and by the 
European Society of Human Genetics68. These emphasise that best practice 
for variant classification requires variant reporting in the setting of a 
multidisciplinary team (MDT) conference. In addition to the considerations for 
likely pathogenicity described above, it is recommended that additional 
evidence is considered including the likely functional consequences of 
candidate variants from experimental data and genetic considerations such as 
whether genotype and phenotype co-segregate within pedigrees. A scoring 
algorithm based on the strength of different lines of evidence then enables the 
simple classification of candidate variants as pathogenic, likely pathogenic, 
likely benign, benign or uncertain significance69.  The MDT then considers 
whether pathogenic or likely pathogenic variants have a full contribution or 
partial contribution to the phenotype of the case and pedigree. One important 
additional recommendation is that variants of uncertain significance should 
not be used by clinicians for clinical decision-making. The ACMG/AMP 
guidelines further emphasise that variants may be reclassified and require 
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Substantial progress has already been made in genetic diagnosis of IPD 
through the systematic adoption of HTS technologies for gene discovery and 
for clinical diagnosis pathways. Supporting these advances has been the 
refinement of methodologies for describing phenotype, bioinformatic analysis 
of sequence data and systematic evaluation of candidate variants.  
Future priorities are likely to be the expansion of the diagnostic repertoire of 
genetic testing through ongoing gene discovery programmes and the accrual 
of evidence for causality and mutational spectrum of existing IPD through 
systematic analysis of case series. Inevitably, the focus of future gene 
discoveries in IPD is likely to be in non-coding genomic regions, epigenetic 
regulation of platelet specific genes and IPD arising as complex traits with 
multiple contributory pathogenic variants.  
 
Future advances in understanding the genetic repertoire of IPD will require 
timely and effective translation into clinical diagnostic services for IPD, in 
which the emphasis will likely be delivery of cost effective and standardised 
delivery of laboratory sequencing services based on HTS technology 
underpinned by robust variant analysis and reporting processes.  This 
approach has been pioneered by initiatives such as the UK 100,000 Genomes 
Project, which adopted IPD as an eligible group of disorders in 2017 for 
diagnosis through WGS. This initiative alongside other HTS panel services 
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are likely to emerge as a first line diagnostic tool for patients with suspected 
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Figure 1. Syndromic disorders can be represented using Human 
Phenotype Ontology terms. 
The Human Phenotype Ontology (HPO) terms that might be used to describe 
a hypothetical patient with MYH9-related disorder demonstrating 
macrothrombocytopenia, mild bleeding, neutrophil inclusions, chronic kidney 
disease, cataracts and hearing impairment. HPO terms are displayed as a 
directed, acyclic graph generated using the HPO browser (http://human-
phenotype-ontology.github.io/tools.html). The relationships demonstrated are 
unidirectional is-a relationships. Some terms overlap between leading 
classes, and therefore some nodes are connected by more than two edges. 
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Table 1. Genes implicated in inherited platelet disorders 
 Genes MOI 
Predominantly platelet number disorders  
Amegakaryocytic thrombocytopenia with 
radioulnar synostosis* 
HOXA11, MECOM Both AR 














Cyclic thrombocytopenia and 
thrombocythemia 
THPO AD 
DIAPH1-related disorder* DIAPH1 AD 
Familial platelet disorder with predisposition 
to AML 
RUNX1 AD 
Filaminopathy with thrombocytopenia* FLNA XR 
Ghosal syndrome* TBXAS1 AR 
MYH9-related disorders* MYH9 AD 
Recessive microthrombocytopenia FYB AR 
Sitosterolemia with 
macrothrombocytopenia* 
ABCG5, ABCG8 Both AR 
Thrombocytopenia absent radius syndrome* RBM8A AR 
Thrombocytopenia and inflammatory 
disease* 
ARPC1B AR 
Thrombocytopenia, anemia and 
myelofibrosis 
MPIG6B AR 
Thrombocytopenia with abnormalities of 
skin keratinisation* 
KDSR AR 
Thrombocytopenia with myelofibrosis and 
bone defects* 
SRC AD 
Wiskott-Aldrich syndrome* WAS XR 
X-linked macrothrombocytopenia with 
dyserythropoiesis 
GATA1 XR 
   
Predominantly platelet function disorders  
ADP receptor defect P2RY12 AR 
ARC syndrome* VIPAS39, VPS33B Both AR 
Autism and dense granule abnormalities* NBEA AD 
Bernard-Soulier syndrome GP1BA, GP1BB, 
GP9 
All AR 
Bleeding due to glycoprotein VI deficiency GP6 AR 
CalDAG-GEFI deficiency RASGRP2 AR 
Chediak Higashi syndrome* LYST AR 
Deficiency of phospholipase A2, group IVA PLA2G4A AR 
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Glanzmann thrombasthenia ITGA2B, ITGB3 AR, AR 
Gray platelet syndrome NBEAL2 AR 






Leukocyte adhesion deficiency 3 FERMT3 AR 
Paris-Trousseau thrombocytopenia and 
Jacobsen syndrome* 
FLI1 AD 
Platelet type von Willebrand disease GP1BA AD 
Quebec platelet disorder PLAU AD 
Scott syndrome ANO6 AR 
Stormorken syndrome* STIM1 AD 
Thromboxane A2 receptor defect TBXA2R AR 
 
List of genes causally associated with inherited platelet disorders by June 
2018. Although divided into disorders primarily of platelet number or platelet 
function, many disorders may show a combination of these features. AD – 
autosomal dominant. AR – autosomal recessive. MOI – mode of inheritance. * 
indicates those disorders with extra-hematological clinical features.
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Table 2. Comparison of available sequencing techniques 
 Sanger sequencing Gene panel sequencing Whole exome sequencing Whole genome sequencing 
Advantages • Highly focused 
• Rapid, cost-effective 







• Large amount of 
data collected 
• Easy to re-analyse 
at future date 
• Greatest amount of 
data collected 
• Easy to re-analyse 
at future date 
Disadvantages • Time-consuming 




required to account 
for advances in the 
field 
• Technical aspects of 
selective sequence 
capture 
• Cost (relative, at 
present) 
• Lack of non-coding 
sequence 
• Technical aspects of 
selective sequence 
capture 
• Cost (relative, at 
present) 
















• At interface between 
diagnosis and gene 
discovery 
• At interface between 
diagnosis and gene 
discovery 
 
Key advantages and disadvantages of the different sequencing techniques currently used in IPD. Selection of sequencing 
technique may also be influenced by local healthcare funding or commissioning strategies.  
 
